

BIOMARKERS MODULE OF THOMSON REUTERS INTEGRITY



DISCOVER THE BIOMARKERS

- Associated with a disease and confidence-level for each biomarker use
- Affected by modifying target activity
- Available for safety and toxicity use
- For patient stratification
- With the utility to move your compound from discovery to the clinic

WHO CAN BENEFIT

- Discovery Biologists
- Pre-clinical Scientists
- Pharmacologists
- Toxicologists
- Clinical Researchers
- Translational Researchers
- Biomarker Specialists
- Informaticians

THE NEW STANDARD IN BIOMARKER RESEARCH

The *Biomarkers Module of Thomson Reuters IntegritySM* provides a wealth of reliable, high-quality, continually updated information supporting [biomarker research](#) at every stage of drug R&D including:

- Target identification
- Proof of mechanism
- Proof of concept
- Treatment / safety monitoring
- Outcome measurement

The *Biomarkers Module* is the first biomarker database to provide standardized terminology and to classify biomarkers reliably into lifecycle phases and disciplines.

It is designed to help you make better, more informed decisions as you strive to improve cost efficiency, predict and minimize risk and avoid late stage attrition.

RELIABLE DATA, PLACED IN CONTEXT FOR YOU TO ASSESS AT A GLANCE

Drawing on data from a host of sources, such as literature, patents, conferences, and medical meetings, the *Biomarkers Module* is reliable in content, rich in analysis, and backed up by rigorous editorial standards.

Each use of a biomarker is assigned to a lifecycle stage, from discovery to widespread clinical acceptance, so you can assess at a glance the most appropriate biomarker for your project.

By linking to the other reliable, refined, and detailed information in *Thomson Reuters IntegritySM* you can contextualize and assess the relative importance of each biomarker by exploring the related drugs, pharmacological and PK data endpoints, clinical studies, targets, and genes.

Each manually curated record in the *Biomarkers Module* is enriched still further with links to supporting and refuting source documents and includes:


- Biomarker name and synonyms
- Biological entities/processes involved
- All roles or utilities
- Measurement techniques
- Associated drugs and mechanisms of action
- Associated gene variants
- FDA approved kits

The *Biomarkers Module* covers molecular and metabolic biomarkers (genomic, proteomic and biochemical) from all major therapy areas. Imaging biomarkers are included with new standard terminology applied to imaging techniques.

Updated daily, the *Biomarkers Module* helps you to stay on top of new developments in biomarker research. The alerting options allow you to be notified automatically of the most relevant changes in your specific areas of interest. The module is also available as an XML feed for your in-house solutions.

“Nothing comes close to the Biomarkers Module”

HEAD OF DISCOVERY GROUP,
TOP US RESEARCH INSTITUTE



Filter results to focus on the biomarkers most relevant to your needs



THOMSON REUTERS™

BIOMARKERS MODULE DEVELOPMENT

May 2008

Biomarkers: 505

Uses: 3,500

July 2012

Biomarkers: over 15,000

Uses: over 600,000

May 2008	January 2009	July 2009	December 2009	January 2010	July 2010	December 2011	March 2012	April 2012
<ul style="list-style-type: none"> Oncology Cardiovascular Disease Diabetes Immunology Respiratory Diseases Neurological Disorders 	<ul style="list-style-type: none"> Addition of Safety/Tox Biomarkers 	<ul style="list-style-type: none"> Pain Infectious Disease Musculoskeletal and Connective Tissue Disorders Endocrine Disease 	<ul style="list-style-type: none"> New options to search by MoA, Drug Name, and Genetic Variations 	<ul style="list-style-type: none"> Addition of imaging Biomarkers 	<ul style="list-style-type: none"> Expansion to all other therapeutic areas 	<ul style="list-style-type: none"> Addition of Panel Biomarkers 	<ul style="list-style-type: none"> New options to search by Experimental Pharmacology and pharmacokinetics 	<ul style="list-style-type: none"> Bi-directional linkages to <i>MetaCore™</i> to allow users of both products to review the complete landscape around a biomarker and its function in pathways and processes.

The *Biomarkers Module* includes biomarkers having clinical utility, those that have been used in a preclinical setting – possible candidates for translation into the clinic – as well as markers with newly emerging uses which can provide new insight into your biomarker research. As a result it can support researchers from discovery to development.

DISCOVERY BIOLOGISTS HELPING YOU TO:

- Learn the biology of the disease you're working on, and understand the current research situation regarding biomarkers in your therapy area.
- Choose the biomarker that will give early indications on whether modifying a potential target has a positive outcome on the disease process.

PRE-CLINICAL SCIENTISTS HELPING YOU TO:

- Find the biomarkers that show the effects of your compound on the disease state.
- Select suitable biomarkers for use in safety and efficacy studies to give early indication of toxicity and proof of concept.

CLINICAL SOCIETIES AND REGULATORY AUTHORITIES HELPING YOU TO:

- Substantiate claims and develop clinical guidelines by consulting a body of carefully curated biomarker information.

CLINICAL RESEARCHERS HELPING YOU TO:

- Find the population that will respond best to the particular treatment.
- Discover and identify which biomarkers to use to advance the design and efficacy of your studies and improve your probability of success.

TRANSLATIONAL RESEARCHERS HELPING YOU TO:

- Connect experimental research and clinical studies for pivotal insights.
- Assign the right biomarker to the right project as early as possible.
- Evaluate the strength of evidence (both supporting and refuting) to assess the relative merits of a biomarker for your own research.

BIOMARKERS MODULE AND METACORE THE PERFECT COMBINATION FOR BIOMARKER RESEARCH*

With direct bi-directional links to *MetaCore* you can not only identify and employ biomarkers which have been researched before, but you can also understand the context in molecular cell biology and pathways to understand the disease better. If you are interested in new biomarker discovery and validation then the combination of *the Biomarkers Module* and *MetaCore* delivers the insight and knowledge to advance your research.

*Subscription to both products required.

IP & SCIENCE REGIONAL OFFICES

North America

Philadelphia +1 800 336 4474

+1 215 386 0100

San Diego +1 858 273 8616

Latin America

Brazil +55 11 8370 9845

Other countries +1 215 823 5674

Europe, Middle East and Africa

Barcelona +34 93 459 2220

London +44 20 7433 4000

Asia Pacific

Singapore +65 6775 5088

Tokyo +81 3 5218 6500

For a complete office list visit:

ip-science.thomsonreuters.com/contact

Contact us to find out more about the *Biomarkers Module* or visit go.thomsonreuters.com/integrity

